Ascendis Pharma A/S (FRA:A71)
177.00
+6.00 (3.51%)
At close: Dec 5, 2025
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 213.63M EUR in the quarter ending September 30, 2025, with 269.40% growth. This brings the company's revenue in the last twelve months to 646.55M, up 97.46% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
646.55M
Revenue Growth
+97.46%
P/S Ratio
16.69
Revenue / Employee
635.74K
Employees
1,017
Market Cap
10.79B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Ascendis Pharma News
- 7 days ago - FDA Extends Review for Ascendis Pharma's (ASND) TransCon CNP - GuruFocus
- 7 days ago - Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Benzinga
- 7 days ago - Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Benzinga
- 9 days ago - Is the Market Bullish or Bearish on Ascendis Pharma AS? - Benzinga
- 10 days ago - FDA Extends Decision Date For TransCon CNP In Pediatric Achondroplasia - Nasdaq
- 10 days ago - Ascendis Pharma (ASND) Faces FDA Review Extension for TransCon CNP - GuruFocus
- 10 days ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters
- 10 days ago - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewsWire